Intrommune Therapeutics Presents Positive Results of Phase 1 OMEGA Study Investigating the Safety of INT301 Toothpaste for the Treatment of Peanut Allergy
November 09, 2023 11:01 ET | Intrommune Therapeutics
Intrommune Therapeutics Presents Positive Results of Phase 1 OMEGA Study Investigating the Safety of INT301 Toothpaste for the Treatment Peanut Allergy
Pet Allergy Treatment Industry Analysis: Anticipated Market to Reach a Size of US$ 4.1 Billion by 2033, Persistence Market Research
August 24, 2023 08:54 ET | Persistence Market Research
New York, Aug. 24, 2023 (GLOBE NEWSWIRE) -- The global pet allergy treatment market reached a size of US$ 2.1 billion in 2022 and is forecasted to expand at a CAGR of 6.3% from 2023 to 2033,...
The Difference Baker Partners With George Mason University and Sodexo to Create the First True Allergy-Friendly Dining Experience on a U.S. College Campus
August 09, 2023 15:46 ET | The Difference Baker
ASHBURN, Va., Aug. 09, 2023 (GLOBE NEWSWIRE) -- The Difference Baker is thrilled to announce a historic collaboration with George Mason University (GMU) and Sodexo, establishing the first retail...
Intrommune Therapeutics Completes Last Patient Last Visit in the Phase 1 OMEGA Study for Peanut Allergy
July 25, 2023 09:35 ET | Intrommune Therapeutics
NEW YORK, July 25, 2023 (GLOBE NEWSWIRE) -- Intrommune Therapeutics, Inc., a clinical stage biotechnology company developing a patient-friendly treatment platform for peanut and other food...
Sublingual Allergy Immunotherapy Market Size to Surpass US$ 1.02 billion by 2033 at a CAGR of 9.1%| Persistence Market Research
June 12, 2023 09:45 ET | Persistence Market Research
New York, June 12, 2023 (GLOBE NEWSWIRE) -- The sublingual allergy immunotherapy (SLIT) market has been experiencing steady growth in recent years due to increasing prevalence of allergies and...
Insights on the Allergy Immunotherapies Global Market to 2028: Rising Awareness of Allergy Immunotherapies, Elevating Income Levels and Increasing Healthcare Expenditure Drives Growth
February 21, 2023 13:18 ET | Research and Markets
Dublin, Feb. 21, 2023 (GLOBE NEWSWIRE) -- The "Allergy Immunotherapies Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2028" report has been added to ...
Intrommune Therapeutics Completes Enrollment in the Phase 1 OMEGA Study for Peanut Allergy
October 26, 2022 09:35 ET | Intrommune Therapeutics
Observed only mild and transient adverse events, with no use of emergency epinephrine Observed 98.4% patient compliance to date with novel OMIT therapeutic modality Safely started patients on dose...
Intrommune Expands and Strengthens Senior Leadership Team
September 28, 2022 09:35 ET | Intrommune Therapeutics
Appointment of Stuart Loesch as President Leverages His Strong Leadership Abilities and Extensive Expertise in Allergy and Pharmaceutical Development Appointment of William Berger, MD, MBA as Head of...
Food Allergy Market [2022-2027] | Global Market Size, Share, Growth Rate, Company Profiles, Demand, Key Finding, Revenue & Gross Margin, Market Drivers, Opportunities, Challenges and Risks Factors Analysis | Market Reports World
June 22, 2022 09:43 ET | Market Reports World
Pune, June 22, 2022 (GLOBE NEWSWIRE) -- Global Food Allergy Market (2022-2027) research report offers an in-depth analysis of market size, share, drivers, restraints, and so on. Moreover, this...
Intrommune Announces Expanded Scope of Phase 1 OMEGA Study in Adults with Peanut Allergy
June 22, 2022 09:31 ET | Intrommune Therapeutics
Amendment to Extend Study Duration to 48 weeks New Maintenance Period Is Designed to Evaluate Safety of INT301 After Long-term Exposure NEW YORK, June 22, 2022 (GLOBE NEWSWIRE) -- Intrommune...